Vertex Pharmaceuticals (VRTX) EBIAT: 2009-2025
Historic EBIAT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $1.1 billion.
- Vertex Pharmaceuticals' EBIAT rose 3.59% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 865.96%. This contributed to the annual value of -$535.6 million for FY2024, which is 114.80% down from last year.
- Vertex Pharmaceuticals' EBIAT amounted to $1.1 billion in Q3 2025, which was up 4.84% from $1.0 billion recorded in Q2 2025.
- Vertex Pharmaceuticals' 5-year EBIAT high stood at $1.1 billion for Q1 2024, and its period low was -$3.6 billion during Q2 2024.
- Moreover, its 3-year median value for EBIAT was $968.8 million (2023), whereas its average is $531.5 million.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 1,109.70% in 2022, then slumped by 492.44% in 2024.
- Quarterly analysis of 5 years shows Vertex Pharmaceuticals' EBIAT stood at $770.1 million in 2021, then increased by 6.34% to $818.9 million in 2022, then increased by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then increased by 3.59% to $1.1 billion in 2025.
- Its EBIAT was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $646.3 million in Q1 2025.